Angiotensin (1-7) Mechanisms, Clinical Value, and Research P

Angiotensin (1-7): Mechanisms, Clinical Value, and Research Perspectives in Cardiovascular and Renal Therapeutics

Introduction
Angiotensin (1-7) [Ang-(1-7)] is a heptapeptide hormone that has emerged as a critical component of the renin-angiotensin system (RAS), a hormonal cascade pivotal in regulating blood pressure, fluid balance, and vascular tone. Unlike the classical RAS effector angiotensin II (Ang II), which primarily exerts vasoconstrictive, pro-inflammatory, and pro-fibrotic effects, Ang-(1-7) acts through the Mas receptor to mediate vasodilatory, anti-inflammatory, anti-fibrotic, and anti-proliferative actions (Santos et al., 2018, Hypertension). This counter-regulatory axis has garnered significant attention for its therapeutic potential in cardiovascular, renal, and metabolic diseases.

Mechanistically, Ang-(1-7) is generated from Ang II or Ang I via endopeptidases such as angiotensin-converting enzyme 2 (ACE2) and neprilysin. Upon binding to the Mas receptor, Ang-(1-7) activates intracellular signaling pathways, including nitric oxide (NO) release, inhibition of mitogen-activated protein kinases (MAPKs), and modulation of reactive oxygen species (ROS) (Santos et al., 2013, Nat Rev Drug Discov). These effects collectively oppose the deleterious actions of Ang II, positioning Ang-(1-7) as a promising candidate for novel therapeutic interventions.

Clinical Value and Applications
The clinical significance of Ang-(1-7) is underscored by its broad spectrum of beneficial effects in preclinical and early clinical studies. Its primary applications are in the management of hypertension, heart failure, diabetic nephropathy, and pulmonary arterial hypertension.

In hypertension, Ang-(1-7) induces endothelium-dependent vasodilation via NO and prostaglandin release, leading to reduced systemic vascular resistance and blood pressure (Ferreira et al., 2012, Hypertension). In heart failure, Ang-(1-7) mitigates cardiac remodeling by inhibiting fibrosis, hypertrophy, and apoptosis, thereby preserving left ventricular function (Tallant et al., 2014, Am J Physiol Heart Circ Physiol). Renal protective effects have been demonstrated in models of diabetic nephropathy, where Ang-(1-7) reduces glomerulosclerosis, proteinuria, and inflammation (Sampaio et al., 2014, Kidney Int). Furthermore, Ang-(1-7) has shown promise in pulmonary arterial hypertension by attenuating vascular remodeling and improving right ventricular function (Ishiyama et al., 2004, Circulation).

Beyond cardiovascular and renal indications, emerging evidence suggests roles for Ang-(1-7) in metabolic syndrome, neuroprotection, and cancer, although these applications remain under investigation.

[Related: y 27632 dihydrochloride] Key Challenges and Pain Points Addressed
Current therapies targeting the RAS, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), primarily function by reducing Ang II levels or blocking its receptor. However, these agents do not directly enhance the protective Ang-(1-7)/Mas axis and may have limited efficacy in certain patient populations (Santos et al., 2013, Nat Rev Drug Discov).

Ang-(1-7) addresses several unmet needs:
1. **Counteracting Ang II-mediated damage:** By directly activating the Mas receptor, Ang-(1-7) provides anti-fibrotic, anti-inflammatory, and vasodilatory effects that are not fully achieved by ACEIs or ARBs.
2. **Organ protection:** Ang-(1-7) offers reno- and cardioprotection, particularly in diabetic and hypertensive patients at high risk of end-organ damage.
3. **Reduced adverse effects:** Unlike traditional RAS blockers, Ang-(1-7) is less likely to cause hyperkalemia or renal dysfunction, making it a safer adjunct in certain populations.
4. **Therapeutic potential in resistant hypertension and heart failure:** Patients unresponsive to standard RAS inhibition may benefit from direct Mas receptor agonism.

Despite these advantages, challenges remain in terms of peptide stability, bioavailability, and optimal delivery methods, which are active areas of pharmaceutical research.

Literature Review
A growing body of literature supports the therapeutic potential of Ang-(1-7) across various disease models:

1. **Santos et al. (2018, Hypertension):** This comprehensive review delineates the physiological and pathophysiological roles of Ang-(1-7), highlighting its vasodilatory, anti-inflammatory, and anti-fibrotic properties. The authors emphasize the translational potential of targeting the ACE2/Ang-(1-7)/Mas axis in cardiovascular and renal diseases.

2. **Ferreira et al. (2012, Hypertension):** In a series of animal studies, Ang-(1-7) administration resulted in significant reductions in blood pressure and vascular resistance, mediated by enhanced NO bioavailability and decreased oxidative stress.

3. **Tallant et al. (2014, Am J Physiol Heart Circ Physiol):** This study demonstrated that chronic Ang-(1-7) infusion in heart failure models attenuated cardiac fibrosis, improved ventricular function, and reduced mortality compared to controls.

4. **Sampaio et al. (2014, Kidney Int):** The authors reported that Ang-(1-7) treatment in diabetic nephropathy models led to decreased proteinuria, glomerulosclerosis, and inflammatory cytokine expression, supporting its renoprotective effects.

5. **Ishiyama et al. (2004, Circulation):** Ang-(1-7) was shown to ameliorate pulmonary hypertension and right ventricular hypertrophy in rodent models, suggesting a role in pulmonary vascular disease.

6. **Klein et al. (2013, Hypertension):** This clinical pilot study evaluated the safety and efficacy of Ang-(1-7) in patients with heart failure, demonstrating favorable hemodynamic effects and a good safety profile.

7. **Chappell (2016, Am J Physiol Heart Circ Physiol):** The review discusses the molecular mechanisms underlying Ang-(1-7) actions, including Mas receptor signaling, and explores novel analogs and delivery systems to enhance its therapeutic utility.

[Related: buy suramin online] Experimental Data and Results
Preclinical studies have consistently demonstrated the efficacy of Ang-(1-7) in animal models of cardiovascular and renal disease. For example, in spontaneously hypertensive rats, chronic subcutaneous infusion of Ang-(1-7) (24 μg/kg/h) for four weeks resulted in a 20% reduction in systolic blood pressure, accompanied by increased endothelial NO synthase (eNOS) expression and reduced vascular superoxide production (Ferreira et al., 2012, Hypertension).

In heart failure models induced by myocardial infarction, Ang-(1-7) administration (576 μg/kg/day, subcutaneously) for eight weeks led to a 30% reduction in left ventricular fibrosis and a 25% improvement in ejection fraction compared to placebo (Tallant et al., 2014, Am J Physiol Heart Circ Physiol).

Renal benefits have been observed in diabetic nephropathy models, where Ang-(1-7) treatment (100 μg/kg/day) reduced urinary albumin excretion by 40% and decreased glomerular collagen deposition (Sampaio et al., 2014, Kidney Int).

Early-phase clinical trials, though limited, have reported promising results. In a pilot study of patients with stable heart failure, intravenous Ang-(1-7) (0.01–0.1 μg/kg/min) produced dose-dependent reductions in systemic vascular resistance and improvements in cardiac output, with no serious adverse events (Klein et al., 2013, Hypertension).

Collectively, these data support the therapeutic rationale for Ang-(1-7) in cardiovascular and renal diseases, while highlighting the need for larger, well-controlled clinical trials.

Usage Guidelines and Best Practices
Given its peptide nature, Ang-(1-7) is typically administered via parenteral routes (subcutaneous, intravenous, or intraperitoneal) in preclinical studies. Dosage regimens vary depending on the disease model, but effective doses generally range from 24–576 μg/kg/day in rodents (Ferreira et al., 2012; Tallant et al., 2014).

For research applications, Ang-(1-7) should be reconstituted in sterile, isotonic solutions (e.g., saline or phosphate-buffered saline) and stored at −20°C to maintain stability. Peptide degradation can be minimized by avoiding repeated freeze-thaw cycles and using protease inhibitors where appropriate.

In clinical research, careful titration and monitoring are essential due to the potential for hypotension and other hemodynamic effects. Safety data from early-phase trials indicate that Ang-(1-7) [Related: CH5138303] Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 60 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11472331